Faiez Zannad, MD, Ph.D
Center of Clinical Investigation, CIC, Inserm and University of Lorraine, CHU de Nancy, Nancy, France
Faiez Zannad is Professor of Therapeutics at the University of Lorraine in Nancy, France. He earned his MD degree and cardiology specialty at the University of Lorraine in 1979 and his Ph.D degree in clinical pharmacology at the University of Lyon in Lyon, France, in 1984; during his Ph.D study, he also completed a fellowship at the MRC Clinical Pharmacology unit, Oxford, UK. Professor Zannad is currently Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux” in the Centre Hospitalier et Universitaire of Nancy.
Professor Zannad coordinates two EU FP7 grants in heart failure: HOMAGE (omics biomarkers for mechanistic phenotyping and prediction of drug response [www.homage‐hf.eu]) and FIBROTARGETS (fibrosis as a biotargets [www.fibrotargets.eu]). As the primary investigator or member of the oversight committees in major clinical trials, Professor Zannad has made significant contributions to evidence‐based heart failure life‐saving therapy, mainly with beta‐blockers (CIBIS) and mineralocorticoid receptor antagonists (RALES, EPHESUS, EMPHASIS‐HF). He pioneered cardiovascular outcome trials in chronic kidney disease (FOSIDIAL, AURORA, ALCHEMIST) and the one of the first cardiovascular safety trials on glucose‐lowering drugs in diabetes (EXAMINE). Professor Zannad has served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on pharmacology and drug therapy, and board member of the ESC Heart Failure Association. He was Founder and
is currently Chairman of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international meeting dedicated to the science of clinical trials, and of the International Workshop on Biomarkers in heart failure. As of July 2016, Professor Zannad has authored more than 530 scientific publications.